In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as McKesson Corporation (NYSE:MCK). McKesson Corporation (NYSE:MCK) offers healthcare services through U.S ...

I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and ...

In other recent news, McKesson Corporation reported its Q3 2025 financial results, highlighting an adjusted earnings per share (EPS) of $10.12, which surpassed the forecast of $9.81.

Fiscal 2026 Revenue Growth Outlook: 11% to 15%. Fiscal 2026 EPS Outlook: $36.75 to $37.55. McKesson Corp (NYSE:MCK) reported a 16% increase in full-year consolidated revenues, reaching a record ...

McKesson MCK-1.15%decrease; red down pointing triangle plans to separate its medical-surgical business into a new company. The pharmaceutical distributor on Thursday said the new company would be ...

IRVING, Texas, May 08, 2025--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson’s Investor ...

(Reuters) -McKesson forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its ...

May 8 (Reuters) - McKesson (MCK.N), opens new tab forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an ...